Part 1: Methods and Analysis

Aims/Objectives

Primary Objectives

  1. Describe patterns of chemotherapy/immunotherapy use.
  2. Describe associated toxicity of chemotherapy/immunotherapy agents

Secondary Objectives

  1. Evaluate the cancer outcomes for the elderly cohort including Disease-Free Survival (DFS), Progression-Free Survival (PFS) and Overall Survival (OS).

Methods

Statistical Analysis

Baseline patient characteristics were summarised using standard descriptive statistics. Continuous variables were reported as means with standard deviation and categorical variables reported as number and percentages. All values excluded missing values.

Overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method. Kaplan-Meier survival curves were constructed to estimate the median OS, DFS and PFS. Stratified survival curves were constructed using prespecified subgroups: age, sex, smoking status, Eastern Cooperative Oncology Group (ECOG) performance status and number of comorbidities. Comparison between the subgroups were performed using the log-rank test. Two-sided p values <0.05 were considered significant.

Statistical analyses were performed using R Version 4.0.3 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria) and RStudio Version 1.4.1103 (RStudio, PBC, Boston, MA). Packages used for analysis included tidyverse, survival, survminer and gtsummary.

Part 2: Patient Demographics

Characteristic N = 921
Age (Years) 80.0 (77.0, 83.0)
Age
75-80 49 (53%)
81-85 32 (35%)
86-90 11 (12%)
Sex
Female 42 (46%)
Male 50 (54%)
Smoking Status
Current 4 (4.8%)
Never 27 (32%)
Previous 53 (63%)
ECOG Scale
0 25 (50%)
1 23 (46%)
2 2 (4.0%)
Number of Comorbidities
0 3 (3.3%)
1 25 (27%)
2 26 (28%)
3 17 (18%)
4 21 (23%)
Tumour Stream
Breast 6 (6.5%)
Colorectal 16 (17%)
Cutaneous SCC 1 (1.1%)
Gynaecology 3 (3.3%)
Head and Neck 3 (3.3%)
Lung 28 (30%)
Melanoma 8 (8.7%)
Merkel Cell 1 (1.1%)
Neurological 2 (2.2%)
Prostate 4 (4.3%)
Sarcoma 2 (2.2%)
Skin 3 (3.3%)
Upper GI 8 (8.7%)
Urogenital 2 (2.2%)
Urological 5 (5.4%)

1 Median (IQR); n (%)

Part 3: Survival Curves

Overall Survival

Quantile Months 95% CI1
50% 27.3 18.6, 45.7

1 CI = Confidence Interval

Disease-Free Survival

Quantile Months 95% CI1
50% 44.7 21.8, -

1 CI = Confidence Interval

Progression-Free Survival

Quantile Months 95% CI1
50% 6.33 4.65, 10.4

1 CI = Confidence Interval

Part 4: Survival Curves- Stratified Subgroups

Overall Survival

Age

Quantile Months 95% CI1
75-80, N = 49
50% 36.8 26.4, -
81-85, N = 30
50% 12.0 7.71, -
86-90, N = 11
50% 25.4 12.0, -

1 CI = Confidence Interval

Sex

Quantile Months 95% CI1
Female, N = 41
50% 27.3 12.0, 45.7
Male, N = 49
50% 28.6 17.9, -

1 CI = Confidence Interval

ECOG Scale

Quantile Months 95% CI1
0, N = 25
50% 28.6 21.0, -
1, N = 23
50% 25.4 10.2, -
2, N = 2
50% 19.6 12.0, -

1 CI = Confidence Interval

Smoking Status

Quantile Months 95% CI1
Current, N = 4
50% 36.8 6.60, -
Never, N = 26
50% 28.6 12.0, -
Previous, N = 52
50% 26.4 18.6, -

1 CI = Confidence Interval

Comorbidities

Quantile Months 95% CI1
0, N = 3
50% 37.5 4.92, -
1, N = 25
50% 21.6 12.0, -
2, N = 25
50% 28.6 12.0, -
3, N = 16
50% 15.5 8.08, -
4, N = 21
50% 28.6 9.47, -

1 CI = Confidence Interval

Disease-Free Survival

Age

Quantile Months 95% CI1
75-80, N = 21
50% 56.4 23.6, -
81-85, N = 8
50% 5.42, -
86-90, N = 3
50% 21.8 1.85, -

1 CI = Confidence Interval

Sex

Quantile Months 95% CI1
Female, N = 16
50% 44.7 18.6, -
Male, N = 16
50% 56.4 21.8, -

1 CI = Confidence Interval

ECOG Scale

Quantile Months 95% CI1
0, N = 7
50% 11.7, -
1, N = 7
50% 21.8 18.6, -
2, N = 1
50% 5.42

1 CI = Confidence Interval

Smoking Status

Quantile Months 95% CI1
Current, N = 2
50% 47.1 23.6, -
Never, N = 9
50% 11.7, -
Previous, N = 17
50% 21.8, -

1 CI = Confidence Interval

Comorbidities

Quantile Months 95% CI1
1, N = 9
50% 23.6 18.6, -
2, N = 14
50% 44.7 10.5, -
3, N = 4
50% 11.5, -
4, N = 5
50% 56.4

1 CI = Confidence Interval

Progression-Free Survival

Age

Quantile Months 95% CI1
75-80, N = 16
50% 7.21 6.60, -
81-85, N = 18
50% 4.82 2.63, -
86-90, N = 6
50% 5.05 2.93, -

1 CI = Confidence Interval

Sex

Quantile Months 95% CI1
Female, N = 18
50% 6.33 4.65, 19.8
Male, N = 22
50% 6.67 4.41, -

1 CI = Confidence Interval

ECOG Scale

Quantile Months 95% CI1
0, N = 7
50% 6.60 2.43, -
1, N = 10
50% 5.63 2.63, -
2, N = 1
50% 25.2

1 CI = Confidence Interval

Smoking Status

Quantile Months 95% CI1
Current, N = 1
50% 3.67
Never, N = 15
50% 6.33 4.82, -
Previous, N = 21
50% 5.63 4.45, -

1 CI = Confidence Interval

Comorbidities

Quantile Months 95% CI1
0, N = 3
50% 25.5 1.62, -
1, N = 12
50% 5.04 2.63, -
2, N = 9
50% 5.59 2.93, -
3, N = 8
50% 7.04 6.33, -
4, N = 8
50% 6.60 4.65, -

1 CI = Confidence Interval